Slide 1: Investor Presentation
Medicure Inc. Investor Presentation 2026 SD-MED-AA-01
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-loo
Slide 3: Medicure's 5 Focuses
Medicure’s 5 Focuses Medicure is an R&D specialty pharmaceutical and pharmacy company focused on the US market 1. Growing sales of ZYPITAMAG® 2. Growing sales of AGGRASTAT® 3. Growing sales of Marley Drug® E-Commerce pharmacy subsidiary 4. Complete Phase 3 Trial of MC-1 for 10 PNPO patients to recei
Slide 4: Medicure's Growth Strategy
Medicure’s Growth Strategy Medicure plans to use its profit to fund R&D and acquisitions Short term: Near term: Long term: Growth of ZYPITAMAG, Build the Marley Drug Development of acquired AGGRASTAT and Marley pharmacy business through new drugs for large unmet Drug pharmacy acquisition and partner
Slide 5: Medicure's Pharmacy Acquisitions – Why?
Medicure’s Pharmacy Acquisitions – Why? • A more efficient distribution and marketing vehicle for ZYPITAMAG – a branded drug • A profitable marketing vehicle for other branded drugs • Saves on high fees to wholesalers and pharmacy benefit managers • Medicure recently acquired Gateway Medical Pharmac
Slide 6: Key Financial Parameters
Key Financial Parameters Net Revenue Contributors to Net Revenue $35.0 35.0 $30.0 30.0 $25.0 25.0 $CAD (M) $CAD (M) $20.0 20.0 AGGRASTAT Pharmacy Business $15.0 15.0 ZYPITAMAG $10.0 10.0 $5.0 5.0 $0.0 0.0 2023 2024 2025 2023 2024 2025 MPH:TSXV 6
Slide 7: Key Financial Parameters
Key Financial Parameters R&D Expenses Change in Net Cash* $3.5 $2.0 $3.0 $1.0 $2.5 $0.0 2023 2024 2025 $CAD (M) $CAD (M) $2.0 -$1.0 $1.5 -$2.0 $1.0 -$3.0 $0.5 $0.0 -$4.0 2023 2024 2025 * During 2025, 2.04M of cash was used for the purchases of Gateway Medical Pharmacy and West Olympia Pharmacy. MPH:
Slide 8: Key Financial Parameters
Key Financial Parameters EBITDA* Net Loss $2.0 2023 2024 2025 $0.0 $1.0 -$1.0 $0.0 -$2.0 2023 2024 2025 $CAD (M) $CAD (M) -$1.0 -$3.0 -$4.0 -$2.0 -$5.0 -$3.0 -$6.0 -$4.0 -$7.0 -$5.0 -$8.0 * Earnings Before Interest, Taxes, Depreciation and Amortization MPH:TSXV 8
Slide 9: Medicure's Leadership Team
Medicure’s Leadership Team Albert D. Friesen James Kinsley Reuben Saba President, Chief Executive Officer Chief Financial Officer Vice President, & Chairman of the Board Business Development • Founded Medicure in • Joined Medicure in 2011 to • VP since 2019 1997 2021 as CFO and rejoined in 2026 • Jo
Slide 10: ZYPITAMAG
$6.5M INDICATION In 2025 High Cholesterol PRODUCT HIGHLIGHTS • Improvements over older statins 5% • Low rates of side effects like muscle pain from the prior year • Doesn’t interact with other medications • Once daily low dose with strong LDL reduction Graphical user interface, website Description a
Slide 11: Medicure's Pharmacy Subsidiaries & E-Commerce Website
Medicure’s Pharmacy Subsidiaries & E-Commerce Website WHAT IS MARLEY DRUG PHARMACY $ 20.3M • A US pharmacy subsidiary licensed to ship FDA approved medications to all 50 states In 2025 • Facilitates Medicure selling ZYPITAMAG directly to consumers 88% HIGHLIGHTS from the prior year* • Increased ZYPI
Slide 12: AGGRASTAT
$5.7M INDICATION Acute Coronary Syndrome In 2025 PRODUCT HIGHLIGHTS • Leading IV antiplatelet in its class 29 % • Used in more than 1,000 hospitals from the prior year • Three formats of the product available Graphical user interface, website Description automatically generated Only Approved Manufac
Slide 13: Development of MC-1 for Rare Pediatric Disease
PHASE 3 CLINICAL STUDY Development of MC-1 for Rare Pediatric Disease Phase 3 study for treatment of rare pediatric disease called PNPO deficiency • Study involves 10-15 patients in US, Europe and Australia • Orphan Drug Status and Fast Track Designation • Study is ongoing • If approved Medicure is
Slide 14: Development of New Chemical Entities
R&D PIPELINE Development of New Chemical Entities Medicure acquired intellectual property related to analogues of pyridoxal 5’-phosphate • Significant advantages over existing compounds • Clinical targets have not yet been disclosed • Targeting large unmet therapeutic needs • Currently in pre-clinic
Slide 15: Thank You for Your Interest
Thank You for Your Interest For Further Information Visit our Websites Investor Relations Medicure.com ir@medicure.com AGGRASTAT.com 1-888-435-2220 (Ext. 228) ZYPITAMAG.com Marley Drug.com Follow us on LinkedIn MPH:TSXV 15